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A recent report by Public Health England [1] describes disparities in the risks and outcomes of COVID-
19 in England. The largest disparity found was for age (those over 80 years were 70 x more likely to die 
than those under 40). Deaths in care homes accounted for more than 25% of the COVID-19 deaths. In 
those of working age, males were twice as likely to die as females. Diagnosis rates and risk of death 
were also higher in deprived areas and in BAME groups. Death rates were high in healthcare workers 
and those who interacted with the public. Comorbidities (diabetes; CHD; kidney disease; pulmonary 
disease; and dementia) were common in those with COVID-19 on the death certificate.  
Many risk factors reflect exposure rates and/or the impaired functioning of different organ systems. The 
aim of the present article is to propose another mechanism that can plausibly account for the above 
disparities. In all virus infections, immune system function will be a crucial factor. One must now ask 
whether there is a possible immunological mechanism that could account for the risk factors seen with 
COVID-19. A recent review [2] argues that previous infection history may be a determinant of risk from 
COVID-19.  
Human  CMV  is  a  highly  prevalent  beta-herpes  virus  that  establishes  life-long  latent  infections. 
Around 30% of young adults in developed countries are infected, increasing  to >60%  in the elderly. In 
LMICs, 100% of young adults are seropositive. CMV plays a significant role in “immunosenescence”, 
and it has been estimated that CMV infection accelerates attrition of the naive T cell pool, which is 
required for generating adaptive immune responses against a novel virus such as SARS-CoV-2, by 
approximately 20 years [2]. 
Mortality rates from Covid-19 have been shown to be increased in certain ethnic groups and differences 
in CMV seroprevalence may act as one potential factor in this regard. The rates of CMV seropositivity 
are very high in populations that have suffered high mortality rates from SARS-CoV-2 such as northern 
Italy, China and Spain.  The influence of CMV on the long term health of females has been shown to be 
less significant than observed in males. CMV is also associated with immune senescence and has been 
linked to a range of cardiovascular and metabolic disorders that are risk factors for COVID-19. 
Moreover, in elderly nursing home residents, high CMV-reactive CD4+ T-cells were associated with an 
increased risk of respiratory viral infection, including other coronaviruses [3]. Epidemiological studies 
show a clear association between CMV serostatus and cardiovascular disease, which may be a 
mechanism that enhances the pathology of SARS-CoV-2 infection. Research has also shown 
interactions between CMV, hyperglycaemia and SARS-CoV-2 infection that could promote tissue 
damage and increase the risk of death in diabetics. 
Another review addresses the relevance of psychological studies of upper respiratory virus infections to 
the COVID-19 pandemic [4]. Psychological stress has been shown to increase susceptibility and 
symptom severity of upper respiratory tract viral illnesses. There has been a sharp increase in mental 
health problems during the COVID-19 pandemic and it has also been shown that high CMV infection 
levels are associated with greater mental health problems.  In many cases the stress induced by 
preventing and managing COVID-19 will resemble PTSD, which has also been shown to lead to an aged 
immune phenotype [5].  
A CMV vaccine is highly desirable to prevent its direct health effects. In the context of COVID-19, 
CMV could be routinely measured as an indicator of risk. Prevention and management of other factors 
(e.g. extreme psychological stress) which are risk factors for an aged immune phenotype is also major 
priority. In some studies CMV has been shown to have a negative impact on vaccine responses in older 
people [6] and this should be taken into account when evaluating the efficacy of vaccines for COVID-
19. 
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The issue of “immunosenescence” is more complicated and requires further investigation as it has often 
been considered the cause of increased incidence and severity of infectious diseases and poorer response 
to vaccination in older adults [7]. It is also likely to be relevant to increased solid cancers and 
autoimmunity with age. There have been many attempts to identify biomarkers of “immunosenescence” 
but the overall profile from many studies is that the associations between immune risk profiles and 
mortality are context dependent. However, a major clinical impact of specific aged immune phenotypes 
will be as biomarkers for identifying response to novel infections such as SARS-COV-2 [8], and the 
development of successful vaccinations [9]. 
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